EP3979789A1 - Behandlung von saprolegnia - Google Patents

Behandlung von saprolegnia

Info

Publication number
EP3979789A1
EP3979789A1 EP20818734.4A EP20818734A EP3979789A1 EP 3979789 A1 EP3979789 A1 EP 3979789A1 EP 20818734 A EP20818734 A EP 20818734A EP 3979789 A1 EP3979789 A1 EP 3979789A1
Authority
EP
European Patent Office
Prior art keywords
compound
acid
protein
homologous
saprolegnia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20818734.4A
Other languages
English (en)
French (fr)
Other versions
EP3979789A4 (de
Inventor
Vaibhav Srivastava
Sanjiv Kumar
Vincent Bulone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3979789A1 publication Critical patent/EP3979789A1/de
Publication of EP3979789A4 publication Critical patent/EP3979789A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K61/00—Culture of aquatic animals
    • A01K61/10—Culture of aquatic animals of fish
    • A01K61/13—Prevention or treatment of fish diseases

Definitions

  • the present invention generally relates to treatment of saprolegniasis in aquatic animals.
  • the oomycete pathogen Saprolegnia parasitica is an opportunistic facultative parasite causing saprolegniasis in various fish species, amphibians, crustaceans and other aquatic animals, and insects.
  • Virulent strains of S. parasitica cause infection in eggs, juvenile and adult fish leading to huge losses worldwide in fishery industry. If untreated, S. parasitica causes death by hemodilution and osmoregulatory failure.
  • Malachite green was used effectively for the treatment of saprolegniasis until it was banned in 2002 by the United States of America and several countries due to undesirable effects (carcinogenic and mutagenic) on human and animal health. Following the ban, there has been a re- emergence of Saprolegnia infections in aquaculture. With the ban of malachite green efforts have been made to find suitable alternatives.
  • Amphotericin B a commonly used antifungal agent, has also been reported to be effective in controlling the growth of Saprolegnia in catfish.
  • Dioscin an ether-ethyl acetate-methanol derivative from the plant Dioscorea collettii considerably inhibits the growth of Saprolegnia by effectively damaging the mycelium and leading to the accumulation of reactive oxygen species by increasing total antioxidant and superoxide dismutase activity.
  • Cladomarine and cladosporin analogs recently isolated from a deep-sea fungus Penicillium coralligerum YK-247 have been reported as novel anti -Saprolegnia compounds and are potential promising candidates with low toxicity to control saprolegniasis.
  • An embodiment relates to a compound for use in the treatment of saprolegniasis in an aquatic animal.
  • the compound is an inhibitor of a non-homologous essential protein in Saprolegnia.
  • the non- homologous essential protein is essential for a Saprolegnia oomycete and is not homologous to any protein in the proteome of the aquatic animal.
  • the compound is selected from the group consisting of acetohydroxamic acid, azelaic acid, sulfamethoxazole, chloramphenicol, and a combination thereof.
  • compositions for use in the treatment of saprolegniasis in an aquatic animal comprising a first compound and a second compound and the second compound is different from the first compound.
  • the first compound is an inhibitor of a non-homologous essential protein in Saprolegnia.
  • the non-homologous essential protein is essential for a Saprolegnia oomycete and is not homologous to any protein in the proteome of the aquatic animal.
  • the first compound is selected from the group consisting of acetohydroxamic acid, azelaic acid, sulfamethoxazole, chloramphenicol, and a combination thereof.
  • the second compound is selected from the group consisting of triclosan; benzoic acid; acetohydroxamic acid; azelaic acid; sulfamethoxazole; chloramphenicol; NaCI; hydrogen peroxide; peracetic acid; boric acid; an antifungal azole, such as clotrimazole; a saprolmycin, such as saprolmycin A-E; a chitosan; an ordidamycin; bronopol; a 2’, 4’- dihyxychalcone; dioscin; amphotericin B; cladomarine; cladosporin; nikkomycin; and a combination thereof.
  • a further embodiment relates to a method for treating saprolegniasis.
  • the method comprises contacting an aquatic animal with a compound and/or composition as defined above.
  • the system comprises a farming system comprising marine or fresh water and a compound and/or a composition as defined above.
  • the present invention provides compounds useful for controlling Saprolegnia oomycetes and thereby useful for the treatment of saprolegniasis in aquatic animals, including fish.
  • the compounds of the invention are safe to use for the aquatic animals and also for humans.
  • Fig. 1 Schematic representation of the subtractive proteomics approach used for identification of potential effective compounds interacting with the proteins from Saprolegnia parasitica.
  • Fig. 2 Effects of selected compounds on the growth of S. parasitica in liquid Machlis medium.
  • Fig. 3 Representative images of growth of S. parasitica on PDA (Potato Dextrose Agar) plates in the presence of selected compounds after 72 hours of growth at 24°C.
  • F Chloramphenicol (800 mg/ml)
  • G Azelaic acid (800 mg/ml)
  • H Copper sulfate (400 mg/ml)
  • J Malachite green (0.8 mg/ml).
  • Fig. 5 Effect of selected compounds on growth of S. parasitica in liquid Machlis culture medium after 24 hours of growth at 24°C as observed under at 20X magnification (optical microscopy).
  • F Chloramphenicol
  • G Azelaic acid
  • H Copper sulfate
  • I Boric Acid
  • J Malachite Green.
  • Fig. 6 Homology modelling and docking of compounds effective against Saprolegnia growth with their respective target proteins.
  • the present invention generally relates to the treatment of saprolegniasis in aquatic animals.
  • Saprolegniasis also referred to as cotton wool disease, cotton mold or water mold, is a fungal disease of aquatic animals, including fish and fish eggs.
  • Saprolegniasis is usually caused by oomycetes in the genus Saprolegnia and is characterized by white to brownish cotton-like patches on the surface of the skin and/or gills of the aquatic animal.
  • Early lesions consist of pale foci with peripheral areas of erythema and a central zone of lifted scales, which frequently becomes ulcerated, exposing underlying musculature.
  • An aspect of the embodiments relates to a compound for use in the treatment of saprolegniasis in an aquatic animal.
  • the compound is an inhibitor of a non-homologous essential protein in Saprolegnia.
  • the non-homologous essential protein is essential for a Saprolegnia oomycete and is not homologous to any protein in the proteome of the aquatic animal.
  • the compound is selected from the group consisting of acetohydroxamic acid, azelaic acid, sulfamethoxazole, chloramphenicol, and a combination thereof.
  • the compound for use according to the invention is an inhibitor of an essential protein in Saprolegnia.
  • This essential protein is, however, not homologous to any protein in the proteome of the aquatic animal to be treated with the compound.
  • the compound is an inhibitor of a non-homologous essential protein in Saprolegnia.
  • the non-homologous essential protein is regarded as not being homologous to any protein in the proteome of the aquatic animal if a sequence similarity or comparison between the non-homologous essential protein and proteins of the aquatic animal results in an E-value that is more 1.0E-03 (1.0x10 3 ) and a bit score equal to or less than 100.
  • the E-value provides information about the likelihood that a given sequence match is purely by chance. The lower the E-value, the less likely the match is a result of random chance and therefore the more significant the match is.
  • the bit score measures sequence similarity independently of query sequence length and database size and is normalized based on the raw pairwise alignment score.
  • the bit score (SB) is determined by the following formula:
  • bit score is linearly related to the raw alignment score.
  • the higher the bit score the more highly significant the match is.
  • the bit score provides a constant statistical indicator for searching different databases of different sizes or for searching the same database at different times as the database enlarges.
  • the non-homologous essential protein is indispensable and therefore essential for the cellular life of Saprolegnia.
  • inhibition of the non-homologous essential protein by the compound of the embodiments will cause a reduction in the growth of Saprolegnia oomycetes.
  • Saprolegnia may cause saprolegniasis in various aquatic animals including various fish species (van West, 2006), amphibians (Blaustain et al., 1994; Fernandez-Beneitez et al., 2008), crustaceans (Dieguez-Uriveondo et al., 1994; Soderhall et al., 1991) and aquatic insects (Sarowar et al., 2013; Sarowar et al., 2014).
  • the aquatic animal is selected from the group consisting of a fish, an amphibian, a crustacean and an aquatic insect.
  • the aquatic animal is a fish.
  • Fish as used herein includes various developmental stages of fishes, such as fish egg, juvenile fish, fry, fingerling and adult fish.
  • the fish is selected from the group consisting of a brown trout, an Atlantic salmon, a rainbow trout, a coho salmon, a catfish, a pike, an arctic car, an eel, a roach, a carp, a sturgeon, a kissing gourami, a guppy, a swordfish, a tilapia, a cod, a platyfish, a zebrafish, a torafugu, a spotted gar, a medaka, a tetra, a tongue sole, and a killifish.
  • Saprolegniasis is most often caused by oomycetes of the Saprolegnia order.
  • saprolegniasis in the aquatic animal is caused by an oomycete of a Saprolegnia species.
  • the Saprolegnia species is selected from the group consisting of S. diclina and S. parasitica.
  • the Saprolegnia species is S. parasitica.
  • the non-homologous essential protein which the compound of the embodiments targets and inhibits, is preferably not homologous to any protein in the proteome of the aquatic animal and in the proteome of humans. Hence, the compound preferably does not target or inhibit any proteins present in humans. As a consequence, an aquatic animal treated for saprolegniasis by the compound of the embodiments can safely be used as human food.
  • the non-homologous essential protein is selected from the group consisting of SPRG_06801 , SPRG_19504, SPRG_35021 and SPRG_13682.
  • SPRG_06801 is annotated as an urease (EC 3.5.1.5), which is a nickel-dependent amidohydrolase catalyzing the hydrolysis of urea into carbon dioxide and ammonia.
  • the hydrolysis of urea occurs in two stages. In the first stage, ammonia and carbamate are produced. The carbamate spontaneously and rapidly hydrolyzes to ammonia and carbonic acid. Ammonia is an important nitrogen source in bacteria, fungi and plants.
  • SPRG_19504 is a hypothetical protein containing 7,8-dihydro-6-hydroxymethylpterin- pyrophosphokinase (HPPK) and a pterin-binding domain, which belong to the dihydropteroate synthase (DHPS) family.
  • HPPK 7,8-dihydro-6-hydroxymethylpterin- pyrophosphokinase
  • DHPS dihydropteroate synthase
  • HPPK EC 27.6.3
  • DHPS EC 2.5.1.15
  • eubacteria and lower eukaryotes synthesize tetrahydrofolate.
  • SPRG_35021 is predicted to be a 50S ribosomal protein L16 protein.
  • SPRG_13682 is a hypothetical protein with 5'-3' exonuclease activity and an N-terminal resolvase-like domain.
  • the compound is selected from the group consisting of acetohydroxamic acid, azelaic acid, sulfamethoxazole, chloramphenicol, and a combination thereof.
  • the compound could be acetohydroxamic acid; azelaic acid; sulfamethoxazole; or chloramphenicol.
  • the compound is in the form of a combination or mixture of acetohydroxamic acid and azelaic acid; acetohydroxamic acid and sulfamethoxazole; acetohydroxamic acid and chloramphenicol; azelaic acid and sulfamethoxazole; azelaic acid and chloramphenicol; or sulfamethoxazole and chloramphenicol.
  • combinations or mixtures of more than two of the compounds could be used, such as a combination or mixture of acetohydroxamic acid, azelaic acid and sulfamethoxazole; acetohydroxamic acid, azelaic acid and chloramphenicol; acetohydroxamic acid, sulfamethoxazole and chloramphenicol; azelaic acid, sulfamethoxazole and chloramphenicol; or acetohydroxamic acid, azelaic acid, sulfamethoxazole and chloramphenicol.
  • the compound is sulfamethoxazole.
  • the sulfamethoxazole is preferably used in a concentration of at least 100 mg/ml, preferably at least 200 mg/ml, more preferably at least 400 mg/ml, such as at least 600 mg/ml or at least 800 mg/ml.
  • the compound is chloramphenicol.
  • the chloramphenicol is used at a concentration of at least 200 mg/ml, preferably at least 400 mg/ml, more preferably at least 600 mg/ml, such as at least 800 mg/ml.
  • the compound is selected from the group consisting of acetohydroxamic acid, azelaic acid, and a combination thereof.
  • the compound could be acetohydroxamic acid.
  • the acetohydroxamic acid is preferably used at a concentration of at least 100 mg/ml, preferably at least 200 mg/ml, more preferably at least 400 mg/ml, such as at least 600 mg/ml.
  • the compound is azelaic acid.
  • the azelaic acid is preferably used at a concentration of at least 200 mg/ml, preferably at least 400 mg/ml, more preferably at least 600 mg/ml, such as at least 800 mg/ml.
  • concentrations for the various compounds are final concentrations of the compound in a solvent or marine or fresh water volume, in which the aquatic animal to be treated is present.
  • the compound of the embodiments is preferably provided dissolved or dispersed in a solvent.
  • the solvent is selected from the group consisting of water, ethanol, acetone and dimethyl sulfoxide (DMSO), preferably water.
  • water is a preferred solvent for acetohydroxamic acid and azelaic acid
  • DMSO may be used for sulfamethoxazole and ethanol, such as 1 % ethanol, for chloramphenicol.
  • Another aspect of the embodiments relates to a composition for use in the treatment of saprolegniasis in an aquatic animal.
  • the composition comprises a first compound and a second compound that is different from the first compound.
  • the first compound is an inhibitor of a non-homologous essential protein in Saprolegnia.
  • the non-homologous essential protein is essential for a Saprolegnia oomycete and is not homologous to any protein in the proteome of the aquatic animal.
  • the first compound is selected from the group consisting of acetohydroxamic acid, azelaic acid, sulfamethoxazole, chloramphenicol, and a combination thereof.
  • the second compound is selected from the group consisting of triclosan; benzoic acid; acetohydroxamic acid; azelaic acid; sulfamethoxazole; chloramphenicol; NaCI; hydrogen peroxide; peracetic acid; boric acid; an antifungal azole, such as clotrimazole; a saprolmycin, such as saprolmycin A-E; a chitosan; an ordidamycin; bronopol; a 2’,4’-dihyxychalcone; dioscin; amphotericin B; cladomarine; cladosporin; nikkomycin; and a combination thereof.
  • Triclosan is preferably used in a concentration of at least 1 mg/ml, preferably at least 2 mg/ml, such as at least 6 mg/ml and more preferably at least 6 mg/ml, or more, such as at least 8 g/ml, at least 10 mg/ml, at least 20 mg/ml, at least 40 mg/ml, at least 60 mg/ml or at least 80 mg/ml.
  • Triclosan may advantageously be dissolved in acetone, such as 1% acetone.
  • Another example of the second compound is benzoic acid.
  • Benzoic acid is preferably used in a concentration of at least 200 mg/ml, preferably at least 400 mg/ml, and more preferably at least 600 mg/ml, or more, such as 800 mg/ml or 1000 mg/ml. Water may advantageously be used as solvent for benzoic acid.
  • the second compound include NaCI, which is preferably used at a concentration of at least 10 mg/ml, such as at least 15 mg/ml; boric acid, which is preferably used at a concentration of at least 0.1 mg/ml, such as at least 0.5 mg/ml; peracetic acid, which is preferably used at a concentration of at least 1 mg/ml, such as at least 4 mg/ml, including 4-10 mg/ml; hydrogen peroxide, which is preferably used at a concentration of at least 25 nl/ml, such as at least 50 nl/ml, including 5075 nl/ml; clotrimazole, which is preferably used at a concentration of at least 0.5 mg/ml, such as at least 1 mg/ml, including 1-2 mg/ml; bronopol, which is preferably used at a concentration of at least 15 mg/ml, such as at least 30 mg/ml; saprolmycin, which is preferably used at a concentration of at least 2.5
  • a further aspect of the embodiments relates to a method for treating saprolegniasis.
  • the method comprises contacting an aquatic animal with a compound of the embodiments and/or a composition of the embodiments.
  • the method comprise dissolving the compound in a solvent, or the first and second compounds of the composition in a solvent, or the first compound in a first solvent and the second compound in a second solvent, to provide one or more solutions.
  • the contacting step preferably comprises contacting the aquatic animal with the solution(s).
  • the compound(s) or solvent(s) may be added to fresh or marine water in which the aquatic animal is present.
  • the compound(s) or solvent(s) could first be added to the fresh or marine water and then the aquatic animal is submersed into the treated fresh or marine water containing the compound(s) or solvent(s).
  • the method may also comprise removing the aquatic animal from the fresh or marine water comprising the compound(s) or solvent(s).
  • Treating saprolegniasis involves the application or administration of a compound, composition or solvent of the embodiments to the aquatic animal, which suffers from saprolegniasis, has a symptom of saprolegniasis or a predisposition toward saprolegniasis, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect saprolegniasis, the symptoms of saprolegniasis, or the predisposition toward saprolegniasis.
  • treatment of an aquatic animal in which no symptoms or clinically relevant manifestations of saprolegniasis have been identified is preventive or prophylactic therapy
  • clinical, curative, or palliative treatment of an aquatic animal in which symptoms or clinically relevant manifestations of saprolegniasis have been identified generally does not constitute preventive or prophylactic therapy. Treating thereby encompasses inhibiting or preventing saprolegniasis in an aquatic animal.
  • Treatment of saprolegniasis in an aquatic animal comprises inhibiting or preventing colonization of infectious stages of Saprolegnia or killing of infectious and/or multiplying stages of Saprolegnia like hyphae. Treating saprolegniasis in an aquatic animal and preventing saprolegniasis progression may include alleviating or preventing symptoms, saprolegniasis associated with Saprolegnia infections, thereby curing an infection and restituting the health of the aquatic animal or through prophylactic treatment, preventing clinical manifestation of saprolegniasis to occur.
  • the previously described embodiments with regard to examples of aquatic animals, examples of Saprolegnia oomycetes, examples of solvents and examples of concentrations of the compounds also apply to this aspect of the embodiments.
  • Yet another aspect of the embodiments includes a system for fish farming.
  • the system comprises a farming system comprising marine or fresh water and a compound and/or composition of the embodiments.
  • system also comprises fishes present in the marine or fresh water in the farming system.
  • the system is preferably a fish farming or pisciculture system used for raising fish commercially in tanks or enclosures, such as fish ponds, usually for food.
  • the farming system may, thus, be in the form of a tank, a fish pond, a fish cage in a lake, bayous, pond, river or ocean, and the like.
  • the whole proteome of Saprolegnia parasitica CBS 223.65 was analyzed to identify non-homologous essential proteins that could be targeted with inhibitors with an aim to control saprolegniasis in aquaculture. Selected inhibitors were tested in vitro for their efficacy in arresting the growth of S. parasitica and several inhibitors with high in vitro efficacy in controlling the growth of S. parasitica were reported.
  • the complete proteome of Saprolegnia parasitica CBS 223.65 was retrieved from the NCBI database.
  • the conserved domains in the proteins were predicted using pfam v31.0 (Finn et al., 2016) and conserveed Domain Database (CDD) (Marchler-Bauer et al., 2017).
  • Protein sequences from human ( Homo sapiens GRCh38.p11) and 15 fish genomes (completed to the Chromosome assembly level) (Table 1) were compared with the proteins from S. parasitica using blastp (BLAST 2.2.31 +).
  • the DrugBank database (Wishart et al., 2018) is a unique collection of bioinformatics and cheminformatics resources combining drug data along with the target information. Potential target proteins (non-homologous essential proteins) from S. parasitica were searched against the DrugBank database (v5.1.1) using blastp (E-value 1.0E-05, bitscore >100). Proteins from S. parasitica with significant hits against the DrugBank database were further considered. Among these, only Food and Drug Administration (FDA) approved compounds were selected for in vitro testing (Table 2).
  • FDA Food and Drug Administration
  • the homology models of the predicted drug targets in S. parasitica were generated by comparative modeling using CPHmodels-3.2 Server (Nielsen et al., 2010). The details about the proteins and templates used are listed in Table 3.
  • the generated models were further minimized through Steepest Descent followed by the Conjugate gradient method in the Discovery Studio 2.5 software (BIOVIA, 2018). These models were also used for molecular docking with selected candidate drugs using AudoDock Vina (Trott and Olson, 2010) in PyRx (Dallakyan, 2008) with default parameters. Three dimensional structures of drug molecules were obtained from the DrugBank database and minimized in PyRx before docking. Docked complexes were further visualized and analyzed using PyMol (Seeliger and de Groot, 2010).
  • Saprolegnia strain and culture conditions S. parasitica (CBS223.65) cultures were maintained at 24°C by inoculating Potato Dextrose Agar (PDA) with infected agar plugs and transferring them to a fresh plate every 15 days. Saprolegnia was also sub-cultured and grown in liquid Machlis medium (Machlis, 1953). Screening of potential inhibitors
  • sesame seeds were sterilized (121 °C for 20 minutes) and sprinkled over the PDA plates. These plates were inoculated with a Saprolegnia infected agar plug at the center and were incubated at 24°C for 5 days until seeds were infected. Subsequently, Saprolegnia- colonized sesame seeds were transferred to a 24-well flat bottom tissue culture plate containing 1 ml Machlis medium with appropriate dilutions of the compounds and controls. The dose-dependent effect of each compound was tested at various concentrations.
  • the effect of different compounds on the growth of S. parasitica on PDA plates was also examined.
  • the PDA plates were prepared with the minimum inhibitory concentration of compounds and controls as inferred from the results of growth inhibition in liquid Machlis medium. Radial growth of S. parasitica was measured (diameter in mm) at 0, 24, 48, and 72 h at 24°C on PDA plates inoculated with an infected agar plug (5 mm).
  • proteins were subjected to blast against the proteins from human and 15 fish genomes (see Table 1). Among 20,121 predicted proteins from S. parasitica, a total of 5,990 proteins were homologous to either human or fish proteins and, thus, were removed. The remaining 14,131 non-homologous proteins were considered for further analysis.
  • echinocandins i.e., caspofungin, anidulafungin and micafungin, were predicted to interact with at least nine of the b-1 ,3-D-glucan synthases required for the synthesis of b-1 ,3-D-glucan.
  • Echinocandins are well characterized antifungal agents, predicted to interact with proteins containing the 1 ,3- b-glucan synthase domain required for the biosynthesis of b-1 ,3-D-glucan, a major component of oomycete cell wall similar to callose from plants.
  • the protein 1 ,3-b-glucan synthase being unique to fungal cell wall with no mammalian homologue is a favored target for these antifungal drugs.
  • CDD analysis of the whole proteome led to the identification of at least ten proteins that belong to the glucan synthase superfamily, including SPRG_05460, which was not identified in the in silico screening as interacting partner with echinocandins.
  • Another compound, picric acid has been used as antiseptic for a very long time and was predicted to inhibit S. parasitica by binding at least eight proteins from the pathogen.
  • Citric acid was predicted to interact with at least four proteins from S. parasitica, including two uncharacterized proteins (SPRG_06530 (probable FtsZ), SPRG_11850 (phosphoribosylaminoimidazole carboxylase (NCAIR synthetase)) and with tryptophan synthase (SPRG_05079) and the cell division protein FtsZ (SPRG_11942). Tryptophan synthase, which catalyzes the final step in tryptophan biosynthesis, is absent in mammals, which makes it an attractive target for other pathogens. The cell division protein FtsZ has been reported as potential drug target in various bacterial pathogens.
  • Formic acid was predicted to interact with at least three chorismate binding enzymes, the anthranilate synthase proteins SPRG_06062, SPRG_12737, and SPRG_16397. Antimicrobial activity of formic acid has also been reported previously on various bacterial and yeast pathogens.
  • Artenimol is predicted to interact with at least two proteins, namely SPRG_00366 and SPRG_09913, which are a pyridoxal biosynthesis lyase PdxS and a negative regulator of GroEL domains, respectively. Artemisinin has been shown to be active against certain tumor cells, virus, malarial protozoa and various plant pathogenic fungi.
  • Sulfonamides such as sulfamethoxazole, were predicted to interact with the protein SPRG_19504 in S. parasitica, which corresponds to a 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase (HPPK) with a pterin binding domain, which belong to the dihydropteroate synthase (DHPS) family.
  • HPPK 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase
  • DHPS dihydropteroate synthase
  • DHPS Dihydropteroate synthase
  • DHFR dihydrofolate reductase
  • Quaternary ammonium compounds like cetrimonium and didecyldimethylammonium were predicted to interact with SPRG_00820, a hypothetical protein with mycolic acid cyclopropane synthetase domain. Antimycotic activity of cetrimide, without showing pathological effect to the eye corneal tissues, was reported against fungal keratitis caused by Fusarium solani. Similarly, didecyldimethylammonium chloride (DDAC) was able to inactivate photosystem II (PSII) efficiency and disintegrate marine phytoplankton species and it was also found effective against Escherichia coli by bleb formation in the cell membrane causing leakage of the intracellular molecules and subsequent death of the cells.
  • DDAC didecyldimethylammonium chloride
  • PSII photosystem II
  • Triclosan and triclocarban are commonly used broad-spectrum antibacterial and antifungal agents that block fatty acid synthesis by inhibiting enoyl-ACP reductase. They were predicted to interact with the protein SPRG_20215 in S. parasitica, an uncharacterized protein with a short-chain dehydrogenases/reductases (SDR) domain. Triclosan has been found to be effective against various gram-negative, gram-positive bacteria, as well as Mycobacteria, Plasmodium falciparum, wherein it is also targeting dihydrofolate reductase, and Leishmania panamensis with no toxicity towards mammalian cells up to 200 mg/ml.
  • SDR short-chain dehydrogenases/reductases
  • Benzimidazoles (albendazole and thiabendazole) were predicted to interact with the protein SPRG_07119, which contains an FAD-binding domain and is structurally similar to the fumarate reductase 2 (PDB 5GLG) from Saccharomyces cerevisiae.
  • the protein is also the target of the FDA- approved inhibitors albendazole and thiabendazole.
  • Benzimidazoles are commonly used fungicides and anthelminthic drugs that specifically inhibit microtubule assembly.
  • Urease inhibitors (acetohydroxamic acid and ecabet) were predicted to interact with the protein SPRG_06801 , annotated as urease (EC 3.5.1.5), which is a nickel-dependent amidohydrolase that catalyzes the decomposition of urea into carbamate and ammonium ion, constituting an important nitrogen source in bacteria, fungi and plants. Urease activity has been reported in Cryptococcus gattii and the recently discovered novel systemic fungal pathogen Emergomyces africanus. Urease is considered critical and is explored as a crucial target for antibacterial agents. This protein is a known target and has two FDA-approved inhibitors, acetohydroxamic acid and ecabet.
  • Azelaic acid was predicted to interact with SPRG_13682, a hypothetical protein with 5'-3' exonuclease activity and an N-terminal resolvase-like domain. Azelaic acid has been found effective against various gram-positive and gram-negative pathogens by inhibiting several oxidoreductive enzymes and impeding glycolysis.
  • Chloramphenicol was predicted to inhibit the SPRG_35021 (50S Ribosomal protein L16) protein. Chloramphenicol is a common anti-bacterial agent that acts by inhibiting protein synthesis and is considered fungistatic. It has been recently reported to have variable degree of inhibitory effect in Phytophthora oomycetes. Even though effective, chloramphenicol resistant strains of Phytophthora have been reported.
  • Tromethamine was predicted to interact with a hyptothetical protein SPRG_04175, which contains Biotin and Thiamin Synthesis associated domain. Glycerin was predicted to interact with the SPRG_01876 protein, a histidinol dehydrogenase. Glycerin has been explored previously for its antibacterial activity.
  • Benzoic acid a commonly used food preservative to prevent growth of yeast and molds, was predicted to interact with SPRG_02663, a hypothetical protein with an X-Pro dipeptidyl-peptidase C-terminal non- catalytic domain.
  • DrugBank compounds which were predicted to interact/inhibit non-homologous proteins from S. parasitica, 10 compounds were tested in vitro for their effectiveness (Table 5), along with copper sulfate, boric acid and malachite green as positive controls and solvents as negative control (see Material and Methods).
  • Solvents used for preparing stock solutions of the selected compounds i.e., water, DMSO, ethanol and acetone, were also tested for their effect and did not show any growth inhibition of S. parasitica up to 1% v/v solvent concentration (Figs. 2A and 2B). Growth inhibition by DMSO and ethanol was observed at a solvent concentration higher than 2% v/v, but no inhibition was observed for water and acetone up to solvent concentrations of 10% v/v.
  • Triclosan and triclocarban were predicted to target the protein SPRG_20215. Triclosan was found to be very effective when tested on liquid Machlis medium with the lowest concentration (MIC100) of 4 mg/ml (Fig. 2C) and significant levels of inhibition were even observed even at a lower concentration (2 mg/ml).
  • MIC100 concentration of 4 mg/ml
  • Benzoic acid targeting hypothetical protein SPRG_02663
  • acetohydroxamic acid targeting urease SPRG_06801
  • sulfamethoxazole 800 mg/ml
  • chloramphenicol 800 mg/ml
  • azelaic acid 800 mg/ml
  • Figs. 2F to 2H Glycerol, citric acid, albendazole, and thiabendazole did not show significant inhibitory effect up to 1000 mg/ml or less (Figs. 2I-2L).
  • Compounds significantly inhibiting growth of S. parasitica at a concentration less than 1000 mg/ml were considered effective.
  • Fig. 2 shows the effect of all the compounds tested on the growth of S. parasitica at various concentrations in liquid Machlis medium. Effect of the selected compounds on S. parasitica radial growth
  • Fig. 3 shows the representative images of the growth of S. parasitica on PDA plates.
  • Fig. 4 shows relative growth of S. parasitica on PDA plates at sub-inhibitory concentrations of the tested compounds after 72 hours of growth at 24°C.
  • Optical microscopy was performed at a lower concentration than MIC100 to observe the effect of the selected compounds on the growth of S. parasitica.
  • Fig. 5 shows the effect of selected compounds on the growth of S. parasitica in liquid Machlis medium after 24 hours of growth at 24°C as observed by optical microscopy at 20X magnification compared to the controls.
  • untreated mycelium appears as transparent elongated structures (Fig. 5A) under optical microscopy.
  • Hyper-branching of mycelium appears to be a common phenomenon in the presence of some of the drugs arresting the growth of S. parasitica as apparent in Fig. 5. However, hyper-branching towards the tip of the mycelium is neither very pronounced nor observed frequently in an untreated hypha (Fig. 5A).
  • a pronounced hyper-branching of the mycelium was observed for triclosan (4 mg/ml), benzoic acid (400 mg/ml), sulfamethoxazole (400 mg/ml), and boric acid (400 mg/ml).
  • a lower degree of hyper-branching was observed for acetohydroxamic acid (600 mg/ml), chloramphenicol (800 mg/ml), azelaic acid (800 mg/ml), copper sulfate (200 mg/ml), and malachite green (0.8 mg/ml).
  • hyper-branching did not appear to be pronounced in the case of malachite green as compared to the other compounds that arrest the growth of S. parasitica (Fig. 5J).
  • Homology modeling or comparative modeling is the process of generating a three-dimensional (3D) model of a protein sequence using a homologous protein structure as a template.
  • CPHmodels server uses profile-profile alignment guided by protein secondary structure and exposure predictions for template identification (Nielsen et al., 2010).
  • Homology modeling and docking studies were performed with six compounds shown to be effective in in vitro testing along with their respective predicted target proteins.
  • the six target proteins were SPRG_20215, SPRG_02663, SPRG_06801 , SPRG_19504, SPRG_35021, and SPRG_13682.
  • the 3D template structure for each selected proteins and the corresponding percent sequence identity are mentioned in Table 2. Except for protein SPRG_02663, where the sequence identity was 25.5%, all other proteins had significant sequence identity of >30%, allowing the production of reliable 3D protein structures.
  • the docking results showed an approximate binding pattern of the drug molecules with the target proteins.
  • Analysis of the docked complexes, i.e., compounds with their respective proteins, showed considerable number of hydrogen bonding (H-bond) within the protein cavity or the active sites, which supports the binding with their respective proteins (Fig. 6).
  • the docking results further supported the initial screening results and provided evidences for probable mechanism of actions of the six drug- proteins interactions as apparent in the in vitro testing of compounds against S. parasitica.
  • at least 40 compounds along with their probable target proteins were predicted using the whole genome subtractive genomics approach and 10 of these compounds were tested in vitro for their efficacy against the growth of S. parasitica.
  • triclosan was found to be most effective with the lowest MIC100 (4-6 mg/ml), followed by benzoic acid (400-600 mg/ml), acetohydroxamic acid (600-800 mg/ml), sulfamethoxazole (800 mg/ml), chloramphenicol (800 mg/ml), and azelaic acid (800 mg/ml).
  • benzoic acid 400-600 mg/ml
  • acetohydroxamic acid 600-800 mg/ml
  • sulfamethoxazole 800 mg/ml
  • chloramphenicol 800 mg/ml
  • azelaic acid 800 mg/ml
  • Pathogenic fungus contributes to amphibian losses in the Pacific Northwest. Biological conservation 67(3), 251-254.
  • Saprolegnia diclina another species responsible for the emergent disease‘Saprolegnia infections’ in amphibians. FEMS Microbiology Letters 279(1 ), 23-29.
  • CDD/SPARCLE functional classification of proteins via subfamily domain architectures. Nucleic Acids Res 45(D1), D200-D203. doi: 10.1093/nar/gkw1129.
  • Saprolegnia strains isolated from river insects and amphipods are broad spectrum pathogens. Fungal Biology 118(7), 579-590.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20818734.4A 2019-06-05 2020-05-07 Behandlung von saprolegnia Pending EP3979789A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1950670 2019-06-05
PCT/SE2020/050468 WO2020246927A1 (en) 2019-06-05 2020-05-07 Treatment of saprolegniasis

Publications (2)

Publication Number Publication Date
EP3979789A1 true EP3979789A1 (de) 2022-04-13
EP3979789A4 EP3979789A4 (de) 2022-08-10

Family

ID=73652039

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20818734.4A Pending EP3979789A4 (de) 2019-06-05 2020-05-07 Behandlung von saprolegnia

Country Status (4)

Country Link
EP (1) EP3979789A4 (de)
CN (1) CN114007414A (de)
CA (1) CA3142601A1 (de)
WO (1) WO2020246927A1 (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100782500B1 (ko) * 2006-05-22 2007-12-05 주식회사 바이넥스 천연 식물 추출물을 이용한 수생곰팡이 억제제
EP1982715A1 (de) * 2007-04-20 2008-10-22 Bayer CropScience AG Verwendung von Fungiziden zur Behandlung von Fischmykosen
WO2012149549A2 (en) * 2011-04-29 2012-11-01 Auburn University Bacillus bacteria for use in treating and preventing infection in aquatic animals
WO2017121464A1 (en) * 2016-01-12 2017-07-20 Fvg Limited Treatment for chitin-containing microorganisms
CN105767593A (zh) * 2016-03-10 2016-07-20 广州聚注专利研发有限公司 一种含植物提取组合物的鱿鱼膏及其制备方法
CN107372342A (zh) * 2017-08-30 2017-11-24 开县泰旭农业综合开发有限公司 一种娃娃鱼养殖过程中的疾病防治方法
CN109198303A (zh) * 2018-11-02 2019-01-15 临沂大学 一种能防治泥鳅水霉病的饲料及饲喂装置

Also Published As

Publication number Publication date
WO2020246927A1 (en) 2020-12-10
EP3979789A4 (de) 2022-08-10
CA3142601A1 (en) 2020-12-10
CN114007414A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
Schaap et al. Encystation: the most prevalent and underinvestigated differentiation pathway of eukaryotes
CA2981773C (en) Synergistic benzoxaborole-containing anti-fungicidal composition
Warrilow et al. Clotrimazole as a potent agent for treating the oomycete fish pathogen Saprolegnia parasitica through inhibition of sterol 14α-demethylase (CYP51)
Chang et al. Dopamine depresses immunity in the tiger shrimp Penaeus monodon
Arockiaraj et al. A novel murrel Channa striatus mitochondrial manganese superoxide dismutase: gene silencing, SOD activity, superoxide anion production and expression
Zahran et al. Evidence for synergism of the antimicrobial peptide piscidin 2 with antiparasitic and antioomycete drugs
Kumaresan et al. Impacts of environmental and biological stressors on immune system of Macrobrachium rosenbergii
Kumar et al. Identification of growth inhibitors of the fish pathogen Saprolegnia parasitica using in silico subtractive proteomics, computational modeling, and biochemical validation
JP7422669B2 (ja) 魚類の体表の寄生虫感染症の処置
Ma et al. Osmoregulation by the myo-inositol biosynthesis pathway in turbot Scophthalmus maximus and its regulation by anabolite and c-Myc
Kestrup et al. Differential infection of exotic and native freshwater amphipods by a parasitic water mold in the St. Lawrence River
Fuangsawat et al. Sensitivity comparison of pathogenic aquatic fungi hypha to sodium chloride, hydrogen peroxide, acetic acid and povidone iodine.
Koner et al. Molecular characterization of superoxide dismutase and catalase genes, and the induction of antioxidant genes under the zinc oxide nanoparticle-induced oxidative stress in air-breathing magur catfish (Clarias magur)
Bu et al. Gene characteristics, immune and stress responses of PmPrx1 in black tiger shrimp (Penaeus monodon): insights from exposure to pathogenic bacteria and toxic environmental stressors
Orzoł et al. Levofloxacin is phytotoxic and modifies the protein profile of lupin seedlings
EP3979789A1 (de) Behandlung von saprolegnia
Li et al. Immune function of cytosolic manganese superoxide dismutase from Macrobrachium rosenbergii in response to bacterial infection
Qian et al. Molecular characterization and expression of sirtuin 2, sirtuin 3, and sirtuin 5 in the Wuchang bream (Megalobrama amblycephala) in response to acute temperature and ammonia nitrogen stress
Xiu et al. Molecular characterization and expression analysis of extracellular copper/zinc superoxide dismutase (ecCuZnSOD) from oriental river prawn, Macrobrachium nipponense
Tkachenko et al. LIPID AND PROTEIN OXIDATION IN THE MUSCLE TISSUE OF GRAYLING (THYMALLUS THYMALLUS LINCK) AFTER CHLORAMINE-T DISINFECTION
Guragain et al. Phenylalanine hydroxylase RNAi knockdown negatively affects larval development, molting and swimming performance of salmon lice
Wang et al. Isolation and identification of Saprolegnia parasitica from grass carp and screening of sensitive drugs
KR101588550B1 (ko) 살충 방법
Abdel-Radi et al. Molecular characterization and phylogenetic analysis of parasitic copepoda; Ergasilus sieboldi isolated from cultured gilthead sea bream (Sparus aurata) in Egypt, associated with analysis of oxidative stress biomarkers
Liu et al. An amine oxidase gene from mud crab, Scylla paramamosain, regulates the neurotransmitters serotonin and dopamine in vitro

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20220707

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/635 20060101ALI20220701BHEP

Ipc: A61K 31/20 20060101ALI20220701BHEP

Ipc: A61K 31/10 20060101ALI20220701BHEP

Ipc: A61K 31/42 20060101ALI20220701BHEP

Ipc: A61K 31/194 20060101ALI20220701BHEP

Ipc: A61K 31/165 20060101ALI20220701BHEP

Ipc: A61K 31/16 20060101ALI20220701BHEP

Ipc: A01K 61/13 20170101AFI20220701BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240613

17Q First examination report despatched

Effective date: 20240701